Embecta (EMBC) CEO Dev Kurdikar joins Oliver Renick to give an overview of the company and discuss its 2Q earnings. He also talks about the impact of GLP-1 drugs. He then goes over the diabetes treatment market, as well as other emerging markets. Tune in to find out more about the stock market today.